NCT06136650 2026-04-15
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
21 trialsNCT00859781 2026-04-08
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06136598 2026-03-19
MK-5684-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT06104449 2026-03-06
MK-5684-005
Merck Sharp & Dohme LLC
Phase 1 Active not recruiting
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT00027859 2023-06-15
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00460031 2020-07-24
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01036594 2020-06-29
Keto/Dex
University of California, San Francisco
Phase 2 Completed
NCT00309894 2019-08-05
Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy
University of California, San Francisco
Phase 2 Completed
NCT00002855 2018-10-31
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00953576 2018-09-04
KHLAD
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT00536991 2017-06-14
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT00895310 2017-03-30
Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy
University of California, Davis
Phase 2 Completed
NCT00002760 2016-06-28
Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00673127 2015-04-22
KHAD
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01267266 2015-04-01
Saracatinib in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00181597 2013-12-03
Trilostane for Androgen-Independent Prostate Cancer
Sanofi
Phase 2 Completed
NCT00559481 2013-02-01
Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy
Roswell Park Cancer Institute
Phase NA Withdrawn
NCT00006371 2012-09-27
A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00705822 2010-11-30
PROSTATA
Sanofi
Phase 3 Terminated
NCT00002881 2010-11-09
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Completed